Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated

Inclusion Criteria: * men from 40 to 75 years old with confirmed prostate adenocarcinoma, prostate biopsy will be performed \<180 days before the date of randomization, * completed assessment of tumor differentiation according to Gleason grading allows to perform stratification; Gleason score ≤ 7 versus Gleason score\> 8, * general condition according to the classification of the Eastern Cooperative Oncology Group (ECOG) 0 - 1), (Appendix 1), * Androgen Deprivation Therapy: prior Radiotherapy (RT) (minimum 3 months before the start of RT), concurrently with RT and after RT during follow-up (24 months) , * high risk of Prostate Cancer progression defined as presence of at least one of the following factors: cT3, Gleason\> 7, PSA\> 20 ng / ml or presence of at least two of cT2c, Gleason 7, PSA in the range of 10.1 ng / ml to 19.9 ng / ml, cT defined by AJCC staging 7 edition, (Appendix 2), * PSA identified at least 10 days after the biopsy or before, and patients receiving fiansteryd 30 days after the cessation of therapy, * no regional and distant metastases confirmed by bone scintigraphy, chest radiograph, computed tomography/magnetic resonance imaging of the pelvis, * signing an informed consent to participate in a medical experiment (radiotherapy + biological material samples) (Annex 3), * morphological and biochemical parameters within normal limits. Exclusion Criteria: * the presence of active cancer except skin cancer preceding period of 5 years prior to randomization, * Early surgery (radical prostatectomy) or pelvic RT, * earlier hormonal therapy than is advocated in this study, * co-morbidities that may significantly affect the expectancy life of the patients * do not meet the criteria for inclusion.